Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma.

Saved in:
Bibliographic Details
Title: Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma.
Authors: Shi, Wenhao1 (AUTHOR), Tang, Haotian1,2 (AUTHOR), Tong, Linjiang2 (AUTHOR), Song, Peiran1 (AUTHOR), Huang, Yuqing1 (AUTHOR), Wan, Zhipeng1 (AUTHOR), Huang, Gege1 (AUTHOR), Liu, Qiupei1,3 (AUTHOR), Zhan, Zhengsheng4 (AUTHOR), Zhou, Yu1 (AUTHOR), Li, Yuantong1 (AUTHOR), Wen, Jiaxin1,2 (AUTHOR), Tang, Bencan3 (AUTHOR), Duan, Wenhu4 (AUTHOR), Ding, Jian2 (AUTHOR), Li, Xiaorui5 (AUTHOR) xiaorui_li@126.com, Xie, Hua1,2 (AUTHOR) hxie@simm.ac.cn
Source: Cancer Cell International. 7/25/2025, Vol. 25 Issue 1, p1-12. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14752867
DOI:10.1186/s12935-025-03902-y